CARDPro China Takes a License from Leighton Technologies
Ryogen Is Awarded Patent for Polynucleotides Related to Tumor-Suppressing Subtransferable Candidate 4
This Patent Brings Ryogen's Gene-Related Portfolio to 30 Issued U.S. Patents
Suffern, N.Y., June 24, 2014 − Ryogen LLC, a genomics R&D company focusing on polynucleotide sequences implicated in human diseases, was awarded a new patent, bringing the total number of U.S. Patents issued to Ryogen to 30.
U.S. Patent No. 8,722,865, titled "Isolated genomic polynucleotide fragments from p15 region of chromosome 11 encoding human tumor suppressing subtransferable candidate 4 (TSSC4)," is the first Ryogen patent to be issued after the seminal Myriad decision of the U.S. Supreme Court that clarified the patentability of genomic constructs.
Here, in a summary form, are five lessons we can learn from Alice:
- Financial methods, even if computerized, are not patentable when well-known methods are merely implemented on a generic computer.
This is not the first instance of a major, high-tech corporation asserting patents for inventions it did not invent and does not practice. This is simply the most recent instance of a major, high-tech corporation asserting patents for inventions it did not invent and does not practice.
If you want to join the Open Source movement, hop aboard an electric car for a ride. Or so says Tesla. Yesterday they opened their patents to all. Their press release begins with a dramatic statement, “Yesterday, there was a wall of Tesla patents in the lobby of our Palo Alto headquarters. That is no longer the case. They have been removed, in the spirit of the open source movement.”